GSK dis­con­tin­ues her­pes ther­a­peu­tic vac­cine af­ter Phase 2 dis­ap­point­ment

GSK is end­ing fur­ther de­vel­op­ment of its ther­a­peu­tic vac­cine for her­pes af­ter the can­di­date failed to pre­vent re­cur­rent symp­tom flare-ups in in­fect­ed adults in a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER